Alberto M Pedroncelli

1.7k total citations
54 papers, 1.2k citations indexed

About

Alberto M Pedroncelli is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Alberto M Pedroncelli has authored 54 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Surgery and 8 papers in Epidemiology. Recurrent topics in Alberto M Pedroncelli's work include Pituitary Gland Disorders and Treatments (49 papers), Growth Hormone and Insulin-like Growth Factors (27 papers) and Adrenal Hormones and Disorders (24 papers). Alberto M Pedroncelli is often cited by papers focused on Pituitary Gland Disorders and Treatments (49 papers), Growth Hormone and Insulin-like Growth Factors (27 papers) and Adrenal Hormones and Disorders (24 papers). Alberto M Pedroncelli collaborates with scholars based in Italy, United States and Switzerland. Alberto M Pedroncelli's co-authors include Maria Fleseriu, Mônica R. Gadelha, Thierry Brue, Ilan Shimon, G. Pagani, Marcello D. Bronstein, Gérald Raverot, Mirtha Guitelman, Rosario Pivonello and M Montini and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, The Lancet Diabetes & Endocrinology and Clinical Endocrinology.

In The Last Decade

Alberto M Pedroncelli

50 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alberto M Pedroncelli Italy	16	1.1k	480	256	97	76	54	1.2k
M Montini Italy	13	744 0.6×	327 0.7×	246 1.0×	48 0.5×	43 0.6×	30	821
Joost van der Hoek Netherlands	11	714 0.6×	329 0.7×	416 1.6×	96 1.0×	59 0.8×	16	988
Fotini Adamidou Greece	14	399 0.3×	204 0.4×	80 0.3×	96 1.0×	41 0.5×	31	634
Cornelia Jaursch-Hancke Germany	10	352 0.3×	290 0.6×	33 0.1×	76 0.8×	43 0.6×	29	519
Leilani B Mercado-Asis Philippines	13	408 0.4×	310 0.6×	39 0.2×	54 0.6×	40 0.5×	59	556
Irina Kline United States	8	350 0.3×	177 0.4×	24 0.1×	241 2.5×	38 0.5×	13	539
Eider Pascual‐Corrales Spain	14	349 0.3×	230 0.5×	71 0.3×	30 0.3×	56 0.7×	52	422
Ryszard Waśko Poland	12	205 0.2×	77 0.2×	80 0.3×	107 1.1×	19 0.3×	52	439
C Augeri Italy	9	137 0.1×	98 0.2×	97 0.4×	75 0.8×	17 0.2×	14	365
Elizabeth Round United States	11	467 0.4×	141 0.3×	108 0.4×	179 1.8×	18 0.2×	12	648

Countries citing papers authored by Alberto M Pedroncelli

Since Specialization

Citations

This map shows the geographic impact of Alberto M Pedroncelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto M Pedroncelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto M Pedroncelli more than expected).

Fields of papers citing papers by Alberto M Pedroncelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto M Pedroncelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto M Pedroncelli. The network helps show where Alberto M Pedroncelli may publish in the future.

Co-authorship network of co-authors of Alberto M Pedroncelli

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto M Pedroncelli. A scholar is included among the top collaborators of Alberto M Pedroncelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto M Pedroncelli. Alberto M Pedroncelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fleseriu, Maria, Rosario Pivonello, John Newell‐Price, et al.. (2025). Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies. Pituitary. 28(1). 22–22. 9 indexed citations

Fleseriu, Maria, Rosario Pivonello, André Lacroix, et al.. (2025). Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4. European Journal of Endocrinology. 193(5). 506–517. 1 indexed citations

Newell‐Price, John, Maria Fleseriu, Rosario Pivonello, et al.. (2024). Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol. Journal of the Endocrine Society. 9(1). bvae201–bvae201. 6 indexed citations

Feldt‐Rasmussen, Ulla, Marek Bolanowski, Shao‐Ling Zhang, et al.. (2024). Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study. Frontiers in Endocrinology. 15. 1250822–1250822. 5 indexed citations

Pivonello, Rosario, Maria Fleseriu, John Newell‐Price, et al.. (2024). Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease. Journal of Endocrinological Investigation. 47(10). 2437–2448. 6 indexed citations

Fleseriu, Maria, Rosario Pivonello, John Newell‐Price, et al.. (2024). 6907 Continued Improvements in Hypertension and Diabetes During Long-Term Osilodrostat Therapy in Patients with Cushing’s Disease: A Pooled Analysis from the Phase III LINC 3 and LINC 4 Studies. Journal of the Endocrine Society. 8(Supplement_1). 1 indexed citations

Ferone, Diego, Joanna L. Spencer-Segal, Güzin Fidan Yaylalı, et al.. (2024). 7376 Efficacy and Safety of CAM2029 in Patients With Controlled or Inadequately Controlled Acromegaly on Standard-of-Care Treatment: Interim Data for the “New to CAM2029” Patient Subgroup in a Phase 3 Study (ACROINNOVA 2). Journal of the Endocrine Society. 8(Supplement_1).

Shimatsu, Akira, Beverly M. K. Biller, Maria Fleseriu, et al.. (2024). Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4). Endocrine Journal. 71(12). 1103–1123. 9 indexed citations

Feelders, Richard A., Maria Fleseriu, Pınar Kadıoğlu, et al.. (2023). Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease. Frontiers in Endocrinology. 14. 1165681–1165681. 11 indexed citations

10.

Biller, Beverly M. K., Maria Fleseriu, Rosario Pivonello, et al.. (2023). THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4. Journal of the Endocrine Society. 7(Supplement_1). 1 indexed citations

11.

Samson, Susan L., Marek Bolanowski, Shao‐Ling Zhang, et al.. (2023). THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide. Journal of the Endocrine Society. 7(Supplement_1). 2 indexed citations

12.

Gadelha, Mônica R., Peter J. Snyder, Przemysław Witek, et al.. (2023). Long-term efficacy and safety of osilodrostat in patients with Cushing’s disease: results from the LINC 4 study extension. Frontiers in Endocrinology. 14. 1236465–1236465. 25 indexed citations

13.

Gadelha, Mônica R., Marie Bex, Richard A. Feelders, et al.. (2022). Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. The Journal of Clinical Endocrinology & Metabolism. 107(7). e2882–e2895. 66 indexed citations

14.

Gadelha, Mônica R., Feng Gu, Marcello D. Bronstein, et al.. (2020). Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocrine Connections. 9(12). 1178–1190. 40 indexed citations

15.

Findling, James W., Maria Fleseriu, John Newell‐Price, et al.. (2016). Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study. Endocrine. 54(2). 516–523. 22 indexed citations

16.

Gadelha, Mônica R., Marcello D. Bronstein, Thierry Brue, et al.. (2014). Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. The Lancet Diabetes & Endocrinology. 2(11). 875–884. 284 indexed citations

17.

Cozzi, Renato, Roberto Attanasio, M Montini, et al.. (2003). Four-Year Treatment with Octreotide-Long-Acting Repeatable in 110 Acromegalic Patients: Predictive Value of Short-Term Results?. The Journal of Clinical Endocrinology & Metabolism. 88(7). 3090–3098. 153 indexed citations

18.

Pagani, G., et al.. (1991). Hypocalcemic effects of rectal and intramuscular administration of synthetic salmon calcitonin.. PubMed. 29(8). 329–32. 8 indexed citations

19.

Pedroncelli, Alberto M, et al.. (1991). A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients. Gynecological Endocrinology. 5(3). 213–216. 3 indexed citations

20.

Pedroncelli, Alberto M, et al.. (1989). Insulin secretion and glucose tolerance in non-insulin dependent diabetic patients after chronic nifedipine treatment. European Journal of Clinical Pharmacology. 36(3). 311–313. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact